Pfizer’s Hemophilia Drug Fidanacogene? No — Marstacimab Wins New NMPA Approval in China

The significance here is less about Pfizer's commercial reach than about the class of therapy: a fixed weekly subcutaneous non-factor option shifts routine prophylaxis away from factor replacement, which matters most for inhibitor patients whose treatment is hardest to manage. China's approval adds a major market to that pathway, though the material gives no pricing, launch timing or reimbursement detail, so access remains unclear. Whether uptake in inhibitor populations — a narrow but high-need group — validates the non-factor approach beyond this label is the open question.